Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Astrana Health, Inc. (ASTH)

36.53 -0.09 (-0.25%)
At close: 4:00:01 PM EDT
36.53 0.00 (0.00%)
After hours: 4:00:16 PM EDT
Trade ASTH on Coinbase
Chart Range Bar
Loading chart for ASTH
  • Previous Close 36.62
  • Open 36.62
  • Bid 26.37 x 200
  • Ask 36.78 x 100
  • Day's Range 35.83 - 36.76
  • 52 Week Range 18.08 - 51.60
  • Volume 236,650
  • Avg. Volume 393,373
  • Market Cap (intraday) 1.812B
  • Beta (5Y Monthly) 1.03
  • PE Ratio (TTM) 44.01
  • EPS (TTM) 0.83
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 51.67
  • Zacks Rating Neutral

Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.

www.astranahealth.com

3,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ASTH
47.24%
S&P 500 (^GSPC)
10.73%

1-Year Return

ASTH
14.84%
S&P 500 (^GSPC)
11.11%

3-Year Return

ASTH
20.52%
S&P 500 (^GSPC)
81.91%

5-Year Return

ASTH
46.77%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 972.52M
Earnings 19.74M
Profit Margin 2.03%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
800M
0.5%
1.0%
1.5%
2.0%

Analyst Insights

View More

Analyst Price Targets

41.00
51.67 Average
36.53 Current
65.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/1/2026
Analyst Freedom Capital Markets
Rating Action Maintains
Rating Buy
Price Action Maintains
Price Target 50 -> 50

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.05%

  • Return on Assets (ttm)

    3.76%

  • Return on Equity (ttm)

    6.90%

  • Revenue (ttm)

    3.84B

  • Net Income Avi to Common (ttm)

    40.55M

  • Diluted EPS (ttm)

    0.83

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    400.79M

  • Total Debt/Equity (mrq)

    163.62%

  • Levered Free Cash Flow (ttm)

    231.19M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: